和黃醫藥(00013.HK)委任蘇朗智為獨立非執行董事
格隆匯5月10日丨和黃醫藥(00013.HK)宣佈,自公司將於2023年5月12日舉行股東周年大會結束時起,蘇朗智教授將獲委任為公司獨立非執行董事、技術委員會成員及審核委員會成員。蘇朗智教授是一位著名的科學家和教育家,於腫瘤學及免疫學方面擁有專業知識和廣泛經驗。和黃醫藥董事會認為蘇朗智教授將對公司做出重大貢獻。
和黃醫藥主席杜志強先生表示:「本人謹代表董事會熱烈歡迎蘇朗智教授加入本公司。我們相信她在腫瘤學及免疫學的生物製藥研究方面的專業知識將為本公司帶來莫大價值,並有助本公司達成目標。」
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.